Vijay G Bhoj
Overview
Explore the profile of Vijay G Bhoj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doshi B, Markmann C, Novak N, Rojas S, Davidson R, Chau J, et al.
Mol Ther
. 2025 Mar;
PMID: 40057826
Neutralizing antibodies (NAb) against adeno-associated virus (AAV) represent a significant obstacle to the efficacy of systemic recombinant AAV vector administration or re-administration. While there are some promising preclinical immunomodulation strategies...
2.
Papadaki G, Li Y, Monos D, Bhoj V
Hum Immunol
. 2024 Nov;
86(1):111180.
PMID: 39591915
With over 30,000 patients having received CAR T cells as a treatment for malignancy, our experience in oncology has facilitated numerous efforts to adapt the CAR therapeutic platform for diseases...
3.
Lee K, Chau J, Suber Y, Sternberg A, Pishko A, George L, et al.
Blood
. 2024 Jul;
144(11):1230-1235.
PMID: 38985830
Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent...
4.
Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D, et al.
Camb Prism Precis Med
. 2024 Mar;
1:e25.
PMID: 38550937
Precision Medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Autoimmune diseases are those in which the body's...
5.
Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, et al.
Cell Rep Med
. 2023 Dec;
4(12):101336.
PMID: 38118406
Pre-existing anti-human leukocyte antigen (HLA) allo-antibodies constitute a major barrier to transplantation. Current desensitization approaches fail due to ineffective depletion of allo-specific memory B cells (Bmems) and long-lived plasma cells...
6.
Mack E, Dougher M, Ginda A, Cahill C, Murter M, Schell K, et al.
Blood
. 2023 Dec;
143(11):1049-1054.
PMID: 38052031
We show that red cell exchange (RCE) treats hyperleukocytosis in acute leukemia. RCE provided similar leukoreduction to standard therapeutic leukoreduction and could be superior in patients with severe anemia or...
7.
Muralidharan K, Agarwal D, Naji A, Bhoj V
J Immunol
. 2022 Nov;
209(10):1811-1816.
PMID: 36344114
Achieving immunosuppression-free immune tolerance to an allograft is one of the central goals of transplantation. In this article, we review recent developments in the fields of T cell-based therapies and...
8.
Parvathaneni K, Torres-Rodriguez K, Meng W, Hwang W, Frey N, Naji A, et al.
JAMA Oncol
. 2021 Nov;
8(1):164-167.
PMID: 34792539
No abstract available.
9.
Kong W, Dimitri A, Wang W, Jung I, Ott C, Fasolino M, et al.
J Clin Invest
. 2021 Aug;
131(16).
PMID: 34396987
Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence,...
10.
Markmann C, Bhoj V
Immunol Rev
. 2021 Aug;
303(1):154-167.
PMID: 34351644
Central to protective humoral immunity is the activation of B cells and their terminal differentiation into antibody-secreting plasma cells. Long-lived plasma cells (LLPC) may survive for years to decades. Such...